PANCREATIC DUCTAL ADENOCARCINOMA

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) to heat and destroy tumor tissue, follow…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests a new drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers. The drug is an antibody-drug conjugate that targets a protein called Claudin 18.2 found on some cancer cells. The tria…

This study tests a new type of radiation therapy that specifically targets cancer cells with a protein called FAP. The treatment uses a radioactive substance (lead-212) attached to a molecule that seeks out FAP-positive tumors. The trial includes 112 adults with advanced pancreat…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arth…

This Phase 2 study tests a new drug called IBI343 combined with two standard chemotherapies (gemcitabine and nab-paclitaxel) in about 389 people with advanced stomach or pancreatic cancers that have a specific protein (CLDN18.2). The main goals are to see if the combination shrin…

This study compares two types of Whipple surgery for people with pancreatic or nearby cancers: the traditional open surgery and a newer keyhole (laparoscopic) approach. About 90 adults with resectable tumors will be randomly assigned to one of the two procedures. The goal is to s…

This phase 2 trial tests a new approach for people with metastatic pancreatic cancer: monthly switching between two standard chemotherapy regimens, NALIRIFOX and GnP. The goal is to see if this alternating schedule can keep the cancer from growing longer than usual. About 41 part…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This early-stage study tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and the best way to give the drug. BI 765049 is designed to he…

This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS gene change. The drug aims to block the cancer's growth signals. The trial will check safety, the right dose, and whether the drug shrinks tumors, al…

This study tests a new drug combo (TQB2868 injection plus anlotinib capsules and chemotherapy) as the first treatment for people with advanced pancreatic cancer. About 80 adults aged 18-75 with confirmed pancreatic ductal adenocarcinoma will take part. The goal is to see if the c…

This early-stage study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors like lung, colorectal, pancreatic, or endometrial cancer that have no…

This early-stage trial tests a new targeted drug (OMTX705) combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study has two parts: first, finding the safest dose of OMTX705, then comparing the new combo against…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This study tests whether adding donated natural killer (NK) immune cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who have had their tumor removed will receive either chemo alone or chemo p…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This phase 2 trial is testing a combination of two immunotherapy drugs, odetiglucan and mitazalimab, as a maintenance treatment for people with unresectable pancreatic cancer that has not worsened after 4-8 months of standard chemotherapy. The study aims to see if this approach c…

This early-stage study tests a new drug that delivers radiation directly to cancer cells in people with advanced pancreatic, lung, breast, or colorectal cancers. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 162 adults whose ca…

This study tests an experimental drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug works by breaking down the mutated protein that helps tumors grow. The study has two parts: first, finding the safest dose, then testing tha…

This study tests a new drug called JPI-547 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 71 adults with locally advanced or met…

This study tests a new drug (HRS-4642) combined with standard chemotherapy and an immunotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if this combination shrinks tumors before surgery and prevents cancer from coming back after surger…

This study tests whether adding drugs that block the tumor's ability to hide from the immune system can make radiation therapy more effective for people with advanced pancreatic cancer. About 60 participants will receive radiation and an immunotherapy drug, with or without additi…

This study tests whether using a special surgical glue (modified N-butyl-2-cyanoacrylate) during pancreas surgery can reduce the risk of a dangerous leak from the pancreas. About 194 people with pancreatic or related cancers who have a soft pancreas will be randomly assigned to r…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This early-phase study tests a new drug, ASP2138, in people with a type of pancreatic cancer that can be removed by surgery. The drug is designed to help the body's immune cells recognize and attack cancer cells that have a specific protein called CLDN18.2. Participants receive o…

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This study tests a new drug called PT886, alone or with chemotherapy or immunotherapy, in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed. The goal is to find the safest dose and see if it helps control the disease. About 258 a…

This study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…

This study tests a more thorough surgery technique for pancreatic head cancer. The goal is to remove more tissue around the tumor to lower the chance of cancer returning. 90 adults with resectable cancer will be followed for 2 years to see if this approach improves survival and r…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on pancreatic cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced pancreatic cancer that has not responded to standard …

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

This study is testing whether adding the experimental drug HRS-4642 to standard chemotherapy can help shrink pancreatic tumors before surgery and prevent them from coming back after surgery. About 30 adults with resectable or borderline resectable pancreatic cancer will receive t…

This study tests whether giving a specific chemotherapy regimen (NALIRIFOX) along with high-dose radiation and another chemo drug (capecitabine) before surgery can help people with pancreatic cancer that has not spread far. The goal is to shrink the tumor enough to allow successf…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have specific changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug, panitumumab. The study is f…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein found on cells that help tumors grow. The trial has two parts: first finding a safe dose, then testing if it works alone or with chemother…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer. The goal is to see if adding the device is safe and helps control the disease. About 30 adults will participate, and they will use t…

This study tests a new treatment for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The goal is to see if this therapy is safe…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with chemotherapy drugs gemcitabine or irinotecan. About 442 participants will take par…

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests a new drug called sacituzumab tirumotecan (MK-2870), given alone or with other cancer treatments, for people with advanced colorectal, pancreatic, or biliary tract cancers that have spread or cannot be removed by surgery. The main goals are to check the drug's sa…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults undergoing pancreas removal for cancer will be randomly assign…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study is testing a software called Lipidica that analyzes fats in the blood to help screen for pancreatic cancer. Researchers will compare results from people with pancreatic cancer to those at high risk (due to family history or genetic factors) to see if the software can t…

This study is testing a new blood test that looks at DNA fragments to find pancreatic neuroendocrine tumors early and to tell them apart from other solid pancreatic tumors. Researchers will enroll 1000 adults with certain pancreatic tumors who haven't had treatment yet. The goal …

This study looks at whether combining special PET and MRI scans with blood tests can detect pancreatic cancer early in people who have pancreatic cysts. The goal is to avoid unnecessary surgery by identifying which cysts are truly dangerous. About 25 adults with high-risk cysts w…

This study tests a new type of PET scan that uses a radioactive tracer called FAPi to find pancreatic cancer that standard CT scans might miss. Researchers will scan 60 adults with pancreatic cancer and compare the results to regular CT scans. The goal is to see if this new metho…

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it wor…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study tests whether an MRI scan can detect tiny liver metastases that standard CT scans miss in people with pancreatic cancer. About 120 adults with newly diagnosed pancreatic cancer will get both a CT and an MRI before treatment. If MRI proves better at finding hidden cance…

This study tests a new type of PET/CT scan that uses a special injection to find cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected spread will…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This pilot study is testing whether a structured program of exercise, nutrition counseling, and support—called prehabilitation—can help adults with pancreatic cancer get stronger before surgery. Twenty participants will follow the program while receiving chemotherapy before their…

This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. Th…

This study tests a new screening program for people aged 50-85 at high risk of pancreatic cancer due to recent diabetes. Participants will get AI-enhanced CT scans and blood tests over time to see if these tools can spot cancer earlier. The goal is to see if this approach is prac…

This study collects blood and tumor samples from 100 people with pancreatic cancer who are about to receive standard chemotherapy before surgery. Researchers will use an artificial intelligence algorithm to analyze the tumor tissue and look for biomarkers that predict which treat…

This study looks at tiny molecules called microRNA in the blood of people with advanced pancreatic cancer. Researchers want to see if these molecules can help diagnose the disease earlier, predict how it will progress, and show whether treatment is working. The study will follow …

This study tests a special MRI scan that uses an experimental contrast agent to see how pancreatic tumors process nutrients. The goal is to predict whether a patient's cancer is responding to treatment earlier and more accurately than standard scans. About 70 adults with advanced…

This study explores whether a special MRI technique called 3D-MRE can measure the stiffness of pancreatic tumors to help predict how the disease will progress. Researchers will enroll 200 adults with pancreatic cancer and compare imaging results with actual tumor hardness and tre…

This study is testing whether a blood test that measures tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is working for metastatic pancreatic cancer. Currently, doctors wait about 8 weeks for a scan. The trial will enroll 50 patients and compare the blood test res…

This study is following 4,000 adults who have pancreatic cysts, which are common findings on scans. The goal is to learn which cysts turn into cancer and which stay harmless. Participants fill out surveys but receive no treatment. The results could help doctors decide when surger…

This study looks for biological markers (biomarkers) that can tell the difference between harmless and dangerous pancreatic cysts called IPMNs. Some IPMNs can turn into pancreatic cancer, but current methods to predict this are not very accurate. Researchers will study tissue and…

This study explores whether a special MRI technique called 3D magnetic resonance elastography (MRE) can accurately measure the stiffness of pancreatic tumors and surrounding scar tissue. Researchers will enroll 200 adults with pancreatic cancer to see if these stiffness measureme…

This study looks at how obesity might help cause pancreatic cancer, especially in African American and non-Hispanic White people. Researchers will compare tumors and fat tissue from 125 adults to find differences that could lead to better treatments. The goal is to understand why…

This study looks at how pancreatic cancer changes over time in people receiving chemotherapy. Researchers take small tissue samples from the tumor at diagnosis and again after treatment to see if the cancer's genetic type has shifted. The goal is to better understand how the canc…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen participants regularly and see which method works best. The goal is to detect cancer …

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how safe it is and how radiation from it spreads through the body. Partici…

This study looks at how pancreatic cancer cells get and use nutrients to grow. Researchers will give a special sugar to 16 patients during surgery to trace the cancer's energy use in the lab. The goal is to find weaknesses in the cancer's fuel system that could lead to new treatm…

This study follows 20,000 people who have a family history of pancreatic cancer or carry certain gene changes that raise their risk. Researchers will track them over time to learn how to detect pancreatic cancer earlier and possibly prevent it. The goal is to improve survival by …

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study is developing a blood test that looks at tiny genetic particles called microRNAs to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will collect blood samples from 200 patients with pancreatic cancer who are about to re…

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…